The price of Arbutus Biopharma Corp (NASDAQ:ABUS) shares last traded on Wall Street rose 2.74% to $3.00.
ABUS stock price is now 13.34% away from the 50-day moving average and 34.86% away from the 200-day moving average. The market capitalization of the company currently stands at $538.47M.
With the price target maintained at $5, Jefferies recently Upgraded its rating from Hold to Buy for Arbutus Biopharma Corp (NASDAQ: ABUS). On February 25, 2021, Jefferies recently initiated its ‘Hold’ rating on the stock quoting a target price of $5, while ‘H.C. Wainwright’ rates the stock as ‘Buy’
In other news, McElhaugh Michael J., Interim President & CEO sold 10,164 shares of the company’s stock on Feb 02 ’24. The stock was sold for $23,504 at an average price of $2.31. Upon completion of the transaction, the Interim President & CEO now directly owns 1,504,793 shares in the company, valued at $4.51 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 02 ’24, Chief Scientific Officer Sofia Michael J. sold 9,982 shares of the business’s stock. A total of $23,083 was realized by selling the stock at an average price of $2.31. This leaves the insider owning 1,485,121 shares of the company worth $4.46 million. A total of 25.34% of the company’s stock is owned by insiders.
During the past 12 months, Arbutus Biopharma Corp has had a low of $1.69 and a high of $3.25. As of last week, the company has a debt-to-equity ratio of 0.08, a current ratio of 5.87, and a quick ratio of 5.87. The fifty day moving average price for ABUS is $2.6470 and a two-hundred day moving average price translates $2.2246 for the stock.
The latest earnings results from Arbutus Biopharma Corp (NASDAQ: ABUS) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at -$0.12, inline with analysts’ expectations of -$0.12. This compares to -$0.14 EPS in the same period last year. The net profit margin was -401.57% and return on equity was -59.99% for ABUS. The company reported revenue of $2.15 million for the quarter, compared to $6.25 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -65.65 percent. For the current quarter, analysts expect ABUS to generate $2.15M in revenue.
